<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="that include but not limited to lopinavirâ€&quot;ritonavir, remdesivir, danoprevir, darunavirâ€&quot;cobicistat," exact="ribavirin" post="and interferon beta, chloroquine, hydroxychloroquine, oseltamivir, umifenovir, pirfenidone, bevacizumab,"/>
 <result pre="28-day mortality. One reason for the lack of efficacy of" exact="lopinavir" post="could be high concentration required to inhibit viral replication"/>
 <result pre="from pneumonia and SARS.[1] In contrast, French clinical trial of" exact="hydroxychloroquine" post="and azithromycin in COVID-19 included hospitalized patients who were"/>
 <result pre="and SARS.[1] In contrast, French clinical trial of hydroxychloroquine and" exact="azithromycin" post="in COVID-19 included hospitalized patients who were asymptomatic or"/>
 <result pre="â€&quot; a large global trial of four drugs â€&quot; remdesivir," exact="chloroquine" post="and hydroxychloroquine, lopinavirâ€&quot;ritonavir, and lopinavir-ritonavir plus interferon-beta.[8] Its simple"/>
 <result pre="outbreaks through an expedited review or unscheduled full committee meetings.[9]" exact="Hydroxychloroquine" post="trial was approved by the French EC within 1"/>
 <result pre="controlled, single-arm proof-of-concept trial in guineaPLoS Med201613e100196726930627 5GautretPLagierJCParolaPHoangVTMeddebLMailheMet al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: Results of an open-label"/>
</results>
